# A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

Source: https://onco.cc/trials/nct02763566/  
OnCo record `nct02763566` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer is a phase 3 interventional study registered as NCT02763566 by Eli Lilly and Company, with 463 participants enrolled, started 2016-12-05 and due to reach its primary completion in 2019-03-29. Interventions recorded: Abemaciclib, Anastrozole, Letrozole, Placebo and Fulvestrant. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02763566
- Phase: 3
- Setting: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 463
- Outcomes: Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI): Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) vs Placebo + NSAI 14.73 months, HR 0.499; Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]: Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) 56% vs Placebo + NSAI 30.3% vs Abemaciclib + Fulvestrant 38.5% vs Placebo + Fulvestrant 7.5%

## Sources

- ClinicalTrials.gov NCT02763566: https://clinicaltrials.gov/study/NCT02763566

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Anastrozole](https://onco.cc/drugs/anastrozole/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct02763566.json